An interventional study of Mobile Health Management Frailty Care Program in Colorectal Cancer, sponsored by Chang Gung University of Science and Technology. Recruiting at 1 site in Taiwan. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Chang Gung University of Science and Technology · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Colorectal Neoplasms with a site in Taiwan — 32 open to participants now, 52 under way, 11 of them phase 3. Colorectal Neoplasms · Taiwan.
Among the 165 studies in Colorectal Neoplasms with a site in Taiwan, this one is the 86th largest by planned enrollment of the 137 interventional ones that give a count, is one of 10 that started in 2024, is one of 30 with no phase, reaches primary completion later than 4 of the 51 other live ones, and was the 141st registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →32 of the 165 studies in Colorectal Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:
Chou-Chen Chen · Sites in Taiwan
Ages 20+
National Taiwan University Hospital · Sites in Taiwan
Ages 40–75
AbbVie · Sites in Taiwan, United States, Belgium and 8 more countries
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in Taiwan, United States, Argentina and 16 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Taiwan, United States, Argentina and 22 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 39 · Phase 3 39 · Phase 4 5
First in 1999; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 209 across the 137 interventional studies, 260 across the 28 observational. Of the 79 that completed or were terminated, 35 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 165 have an industry lead sponsor. The 10 most frequent:
Chang Gung University of Science and Technology is the lead sponsor of 43 studies on the registry; 15 are open to participants now.
Chang Gung University of Science and Technology has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
15 of the studies in Colorectal Neoplasms with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05224518National Taiwan University Hospital Hsin-Chu BranchExercise Intervention to Improve Quality of Life in Patients With Colorectal Cancer | 2026-12-31 |
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
| NCT04482309AstraZenecaA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | 2027-03-23 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 165 studies in Colorectal Neoplasms with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this interventional study is to evaluate the effect of mobile health intervention on frailty, physical fitness, physical activity, and nutritional status of elderly patients with colorectal cancer. The main questions it aim to answer are: 1. Does the mobile health intervention reduce frailty in elderly colorectal cancer patients compared to standard care? 2. Does the mobile health intervention improve physical fitness, physical activity, and nutritional status in elderly colorectal cancer patients compared to standard care? Participants will receive the Mobile Health Management Frailty Care Program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Provide mobile health interventions that combine nutrition and exercise
Behavioral: Mobile Health Management Frailty Care Program
Provide routine care
Through the "LINE" communication software, participants are provided with exercise and nutrition information three times a week, with a total of 36 messages. As well as 6 podcasts of health information and 6 sports videos in total. At weeks 2, 4, and 6, researchers scheduled 5- to 10-minute telephone consultations. Participants can receive guidance through telephone consultations and carry a Xiaomi sports band wearable device to monitor their exercise.
Frailty
Assessing frailty status using the G8 geriatric screening tool. Scores range from 0 to 17, with 0 indicating severe impairment and 17 indicating no impairment. The lower the score, the more frail it is.
Time frame: Pre-test, sixth week after intervention, 13th week after intervention
Physical Activity
Assess physical activity with the International Physical Activity Questionnaire-Short Form. The IPAQ-SF evaluates the number of days and time spent performing MVPA, walking, and sitting in bouts of at least 10 min over the previous 7 days. The summary score is expressed in PA metabolic equivalent of task (MET)-min per day or week.
Time frame: Pre-test, sixth week after intervention, 13th week after intervention
Nutritional Status
Assess nutritional status with Mini Nutritional Assessment-Short Form. The total score is 0-14 points. A score of 12 or more indicates a low risk of malnutrition. A score of 8-11 indicates a potential risk of malnutrition. A score less than 7 indicates a high risk of malnutrition.
Time frame: Pre-test, sixth week after intervention, 13th week after intervention
health-related quality of life
Assessing quality of life using Taiwan Chinese version of European Organization for Research and Treatment of Cancer questionnaires. For all scales, item scores are summed and linearly transformed into a scale ranging from 0 to 100. Higher scores on the functioning scales indicate higher levels of functioning
Time frame: Pre-test, sixth week after intervention, 13th week after intervention
Depression
Assessing depression level using the Geriatric Depression Scale Short Form. The higher the score, the higher the degree of depression. 0-4 indicates normal, 5-10 indicates slight tendency to depression, and 10 or more indicates symptoms of depression.
Time frame: Pre-test, sixth week after intervention, 13th week after intervention
body mass index
Body mass index is calculated by dividing weight (kg) by height (meters) squared. The normal range is 18.5 ≦ BMI \< 24. Less than 18.5 represents underweight; 24 ≦ BMI \<27 represents overweight; 27 ≦ BM I\<30 represents mild obesity; 30 ≦ BMI \<35 represents moderate obesity; BMI ≧35 represents severe obesity.
Time frame: Pre-test, sixth week after intervention, 13th week after intervention
hand grip strength
Hand grip strength (in kilograms) was measured using a digital hand dynamometer (EH101; Camry, Guangdong Province, China). The grip strength of the dominant hand was assessed three times, and the maximal value was considered for analysis. The definition of normal GS according to European Working Group on Sarcopenia in Older People (EWGSOP) was ≥ 30kg in the male and ≥ 20 kg in the female. Weak GS was defined as GS \< 30 kg in the male and GS \< 20 kg in the female.
Time frame: Pre-test, sixth week after intervention, 13th week after intervention
walking speed
Walking speed was measured with a 4-meter walking evaluation with a static start. The 4-m gait speed was assessed to the nearest 0.01 s using a stopwatch. Participants were instructed to walk at their comfortable speed. Walking distance exceeded the required four meters to prevent participants from slowing down before reaching the 4-m line. The fastest time of two trials was used for analyses and gait speed was expressed in m/s. The 0.8 m/s cut-point was used to represent a slow walking speed.
Time frame: Pre-test, sixth week after intervention, 13th week after intervention
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Sep 2025, 19 months after the start.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 19 months is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung University of Science and Technology